- Home
- PGEN
PGEN
Precigen Inc.
as 07-26-2024 4:00pm EST
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | 405.1M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 884.7K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $1.93 | Next Earning Date: | 08-07-2024 |
| Revenue: | $5,439,000 | Revenue Growth: | -76.60% |
| Revenue Growth (this year): | -18.39% | Revenue Growth (next year): | 766.73% |
Stock Insider Trading Activity of Precigen Inc. (PGEN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | PGEN | Director10% Owner | Dec 28 '23 | Buy | $1.41 | 96,686 | $136,327.26 | 1,096,686 | SEC Form 4 |
| KINDLER JEFFREY B | PGEN | Director | Dec 28 '23 | Sell | $1.41 | 96,686 | $136,327.26 | 238,275 | SEC Form 4 |
Latest Precigen Inc. News
PGEN Breaking Stock News: Dive into PGEN Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
Simply Wall St.
12 days ago
Precigen Insiders Added US$1.72m Of Stock To Their Holdings
Simply Wall St.
a month ago
Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
Simply Wall St.
2 months ago
Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
PR Newswire
2 months ago
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
PR Newswire
2 months ago
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
PR Newswire
2 months ago
Precigen Reports First Quarter 2024 Financial Results and Business Updates
PR Newswire
3 months ago
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
Compare PGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PGEN Precigen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.